

Shridar Ganesan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4983149/publications.pdf>

Version: 2024-02-01

105
papers

11,511
citations

47006

47
h-index

30087

103
g-index

110
all docs

110
docs citations

110
times ranked

17131
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker. Biomarker Insights, 2022, 17, 117727192210787.	2.5	11
2	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2022, 40, 1231-1258.	1.6	96
3	Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100477.	3.0	2
4	Reply to T. MÃ©nard. JCO Precision Oncology, 2022, , .	3.0	0
5	Gene expression of adipokines and adipokine receptors in the tumor microenvironment: associations of lower expression with more aggressive breast tumor features. Breast Cancer Research and Treatment, 2021, 185, 785-798.	2.5	10
6	Breast cancer among Asian Indian and Pakistani Americans: A surveillance, epidemiology and end resultsâ€based study. International Journal of Cancer, 2021, 148, 1598-1607.	5.1	10
7	Receptor-Defined Breast Cancer in Five East African Countries and Its Implications for Treatment: Systematic Review and Meta-Analysis. JCO Global Oncology, 2021, 7, 289-301.	1.8	6
8	Emerging strategies for treating metastasis. Nature Cancer, 2021, 2, 258-270.	13.2	71
9	Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer. Case Reports in Oncology, 2021, 14, 931-937.	0.7	8
10	Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer. Frontiers in Genetics, 2021, 12, 706435.	2.3	7
11	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nature Reviews Clinical Oncology, 2021, 18, 773-791.	27.6	198
12	SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis. Oncogene, 2021, 40, 6034-6048.	5.9	9
13	Gene Expression in Barrettâ€™s Esophagus Cell Lines Resemble Esophageal Squamous Cell Carcinoma Instead of Esophageal Adenocarcinoma. Cancers, 2021, 13, 5971.	3.7	2
14	Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing. JCO Precision Oncology, 2021, 5, 1749-1757.	3.0	10
15	The Panâ€Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist, 2020, 25, e39-e47.	3.7	13
16	Biomarkers for Response to Immune Checkpoint Blockade. Annual Review of Cancer Biology, 2020, 4, 331-351.	4.5	29
17	All-FIT: allele-frequency-based imputation of tumor purity from high-depth sequencing data. Bioinformatics, 2020, 36, 2173-2180.	4.1	13
18	Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. Oncology, 2020, 98, 905-912.	1.9	27

#	ARTICLE	IF	CITATIONS
19	Poly (ADP-Ribose) Polymerase Inhibitor Activity in Prostate Cancers Harboring Mutations in DNA Repair Genes: Who Benefits?. JCO Precision Oncology, 2020, 4, 1034-1037.	3.0	6
20	Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response. Nature Cancer, 2020, 1, 923-934.	13.2	67
21	Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes. Cancer Treatment and Research Communications, 2020, 25, 100232.	1.7	7
22	Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. JCO Precision Oncology, 2020, 4, 442-465.	3.0	103
23	Tissue- and development-stage-specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples. Nucleic Acids Research, 2020, 48, 7079-7098.	14.5	12
24	Genomic and immunologic correlates of LAG-3 expression in cancer. Oncoimmunology, 2020, 9, 1756116.	4.6	22
25	A Quasi Birth-and-Death model for tumor recurrence. Journal of Theoretical Biology, 2019, 480, 175-191.	1.7	2
26	A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Pozitotinib. Journal of Thoracic Oncology, 2019, 14, 1982-1988.	1.1	27
27	Association of <i>JAK2</i> -V617F Mutations Detected by Solid Tumor Sequencing With Coexistent Myeloproliferative Neoplasms. JAMA Oncology, 2019, 5, 265.	7.1	9
28	PALB2 connects BRCA1 and BRCA2 in the G2/M checkpoint response. Oncogene, 2019, 38, 1585-1596.	5.9	39
29	Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood, 2018, 131, 2501-2505.	1.4	57
30	Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. Journal of the National Cancer Institute, 2018, 110, 316-320.	6.3	171
31	Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data. JCO Precision Oncology, 2018, 2018, 1-15.	3.0	16
32	Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum. JCO Precision Oncology, 2018, 2, 1-4.	3.0	23
33	Multiple primary malignancies in patients with anal squamous cell carcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 853-857.	1.4	2
34	RET rearrangements are actionable alterations in breast cancer. Nature Communications, 2018, 9, 4821.	12.8	87
35	High-throughput adaptive sampling for whole-slide histopathology image analysis (HASHI) via convolutional neural networks: Application to invasive breast cancer detection. PLoS ONE, 2018, 13, e0196828.	2.5	100
36	Nuclear shape and orientation features from H&E images predict survival in early-stage estrogen receptor-positive breast cancers. Laboratory Investigation, 2018, 98, 1438-1448.	3.7	99

#	ARTICLE	IF	CITATIONS
37	Quantitative nuclear histomorphometry predicts onco-type DX risk categories for early stage ER+ breast cancer. <i>BMC Cancer</i> , 2018, 18, 610.	2.6	67
38	Evidence of Intertissue Differences in the DNA Damage Response and the Pro-oncogenic Role of NF- κ B in Mice with Disengaged BRCA1-PALB2 Interaction. <i>Cancer Research</i> , 2018, 78, 3969-3981.	0.9	10
39	Comprehensive genomic profiling of malignant phyllodes tumors of the breast. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 597-602.	2.5	38
40	BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5631-5638.	7.0	56
41	Roadmap to a Comprehensive Clinical Data Warehouse for Precision Medicine Applications in Oncology. <i>Cancer Informatics</i> , 2017, 16, 117693511769434.	1.9	36
42	Nuclear topology modulates the mutational landscapes of cancer genomes. <i>Nature Structural and Molecular Biology</i> , 2017, 24, 1000-1006.	8.2	28
43	Surveillance nanotechnology for multi-organ cancer metastases. <i>Nature Biomedical Engineering</i> , 2017, 1, 993-1003.	22.5	51
44	Protein-lysine methyltransferases G9a and GLP1 promote responses to DNA damage. <i>Scientific Reports</i> , 2017, 7, 16613.	3.3	28
45	Patient-Derived Xenograft Models of Non-Small Cell Lung Cancer and Their Potential Utility in Personalized Medicine. <i>Frontiers in Oncology</i> , 2017, 7, 2.	2.8	63
46	The DNA repair function of CUX1 contributes to radioresistance. <i>Oncotarget</i> , 2017, 8, 19021-19038.	1.8	21
47	Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells. <i>Oncotarget</i> , 2017, 8, 44639-44653.	1.8	20
48	Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2113.	4.1	165
49	Yin and yang of 4E-BP1 in cancer. <i>Cell Cycle</i> , 2016, 15, 1401-1402.	2.6	7
50	Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. <i>Oncologist</i> , 2016, 21, 1315-1325.	3.7	64
51	A Novel Role of Chromodomain Protein CBX8 in DNA Damage Response. <i>Journal of Biological Chemistry</i> , 2016, 291, 22881-22893.	3.4	11
52	Role of Biomarkers in the Development of PARP Inhibitors. <i>Biomarkers in Cancer</i> , 2016, 8s1, BIC.S36679.	3.6	57
53	Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. <i>Biomarkers in Cancer</i> , 2016, 8s1, BIC.S34417.	3.6	27
54	Precision Medicine: Implications for Science and Practice. <i>Journal of the American College of Surgeons</i> , 2016, 223, 433-439e1.	0.5	6

#	ARTICLE	IF	CITATIONS
55	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. <i>Oncologist</i> , 2016, 21, 762-770.	3.7	119
56	Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. <i>Gynecologic Oncology</i> , 2016, 141, 2-9.	1.4	40
57	Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. <i>Journal of Clinical Investigation</i> , 2016, 126, 2334-2340.	8.2	312
58	Biomarkers for Immunotherapy: Current Developments and Challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e493-e503.	3.8	41
59	The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. <i>Cell Reports</i> , 2015, 13, 1895-1908.	6.4	117
60	Response to Crizotinib in a Patient with MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib. <i>European Urology</i> , 2015, 67, 353-354.	1.9	10
61	Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 57-73.	2.5	27
62	IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5 ⁺ B ϵ and T ϵ cell trafficking to tumor-conditioned media. <i>Immunology and Cell Biology</i> , 2015, 93, 486-499.	2.3	33
63	Next Generation Sequencing As an Aid to Diagnosis and Treatment of an Unusual Pediatric Brain Cancer. <i>Journal of Personalized Medicine</i> , 2014, 4, 402-411.	2.5	0
64	ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic <i>Becn1</i> loss. <i>Autophagy</i> , 2014, 10, 662-676.	9.1	36
65	Male Fertility Defect Associated with Disrupted BRCA1-PALB2 Interaction in Mice. <i>Journal of Biological Chemistry</i> , 2014, 289, 24617-24629.	3.4	65
66	<i>ERG</i> and <i>CHD1</i> heterogeneity in prostate cancer: Use of confocal microscopy in assessment of microscopic foci. <i>Prostate</i> , 2014, 74, 1551-1559.	2.3	13
67	Triple-negative breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2014, 26, 34-40.	2.0	33
68	Mutational Landscape of the Essential Autophagy Gene <i>BECN1</i> in Human Cancers. <i>Molecular Cancer Research</i> , 2014, 12, 485-490.	3.4	167
69	Autophagy Opposes p53-Mediated Tumor Barrier to Facilitate Tumorigenesis in a Model of <i>PALB2</i> -Associated Hereditary Breast Cancer. <i>Cancer Discovery</i> , 2013, 3, 894-907.	9.4	118
70	Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Bra1</i> -Mutated Mouse Mammary Tumors. <i>Cancer Discovery</i> , 2013, 3, 68-81.	9.4	428
71	Multi-Field-of-View Framework for Distinguishing Tumor Grade in ER+ Breast Cancer From Entire Histopathology Slides. <i>IEEE Transactions on Biomedical Engineering</i> , 2013, 60, 2089-2099.	4.2	104
72	Tripartite Motif-containing 33 (TRIM33) Protein Functions in the Poly(ADP-ribose) Polymerase (PARP)-dependent DNA Damage Response through Interaction with Amplified in Liver Cancer 1 (ALC1) Protein. <i>Journal of Biological Chemistry</i> , 2013, 288, 32357-32369.	3.4	53

#	ARTICLE	IF	CITATIONS
73	Metabotropic Glutamate Receptor 1 Expression and Its Polymorphic Variants Associate with Breast Cancer Phenotypes. PLoS ONE, 2013, 8, e69851.	2.5	22
74	PALB2 Interacts with KEAP1 To Promote NRF2 Nuclear Accumulation and Function. Molecular and Cellular Biology, 2012, 32, 1506-1517.	2.3	164
75	Amplified Loci on Chromosomes 8 and 17 Predict Early Relapse in ER-Positive Breast Cancers. PLoS ONE, 2012, 7, e38575.	2.5	33
76	Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. Journal of Clinical Investigation, 2012, 122, 1920-1932.	8.2	101
77	ErbB2, EphrinB1, Src Kinase and PTPN13 Signaling Complex Regulates MAP Kinase Signaling in Human Cancers. PLoS ONE, 2012, 7, e30447.	2.5	26
78	Triple-negative breast cancers and the human mammary epithelial cell hierarchy. Breast Disease, 2011, 32, 49-61.	0.8	2
79	Clinicopathologic Presentation of Asian-Indian American (AIA) Women with Stage 0, I & II Breast Cancer. Journal of Immigrant and Minority Health, 2011, 13, 42-48.	1.6	2
80	BMI1 Is Recruited to DNA Breaks and Contributes to DNA Damage-Induced H2A Ubiquitination and Repair. Molecular and Cellular Biology, 2011, 31, 1972-1982.	2.3	220
81	BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. Journal of Molecular Cell Biology, 2011, 3, 66-74.	3.3	91
82	MYC, PARP1, and Chemoresistance: BIN There, Done That?. Science Signaling, 2011, 4, pe15.	3.6	25
83	A 2D mechanistic model of breast ductal carcinoma in situ (DCIS) morphology and progression. Journal of Theoretical Biology, 2010, 263, 393-406.	1.7	47
84	Expectation-Driven Maximization-Driven Geodesic Active Contour With Overlap Resolution (EMaGACOR): Application to Lymphocyte Segmentation on Breast Cancer Histopathology. IEEE Transactions on Biomedical Engineering, 2010, 57, 1676-1689.	4.2	171
85	53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature Structural and Molecular Biology, 2010, 17, 688-695.	8.2	846
86	Association of Nuclear Localization of a Long Interspersed Nuclear Element-1 Protein in Breast Tumors with Poor Prognostic Outcomes. Genes and Cancer, 2010, 1, 115-124.	1.9	76
87	Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers. Genes and Cancer, 2010, 1, 1063-1073.	1.9	27
88	Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes and Cancer, 2010, 1, 152-163.	1.9	283
89	Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer. Molecular Cancer Research, 2009, 7, 1487-1496.	3.4	40
90	Towards Improved Cancer Diagnosis and Prognosis Using Analysis of Gene Expression Data and Computer Aided Imaging. Experimental Biology and Medicine, 2009, 234, 860-879.	2.4	32

#	ARTICLE	IF	CITATIONS
91	Further Evidence for BRCA1 Communication with the Inactive X Chromosome. <i>Cell</i> , 2007, 128, 991-1002.	28.9	72
92	High Expression of Lymphocyte-Associated Genes in Node-Negative HER2+ Breast Cancers Correlates with Lower Recurrence Rates. <i>Cancer Research</i> , 2007, 67, 10669-10676.	0.9	190
93	The disappearing Barr body in breast and ovarian cancers. <i>Nature Reviews Cancer</i> , 2007, 7, 628-633.	28.4	112
94	X chromosomal abnormalities in basal-like human breast cancer. <i>Cancer Cell</i> , 2006, 9, 121-132.	16.8	736
95	Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. <i>Genes and Development</i> , 2005, 19, 489-501.	5.9	1,122
96	The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 8222-8227.	7.1	332
97	Active Localization of the Retinoblastoma Protein in Chromatin and Its Response to S Phase DNA Damage. <i>Molecular Cell</i> , 2003, 12, 735-746.	9.7	110
98	BRCA1 Supports XIST RNA Concentration on the Inactive X Chromosome. <i>Cell</i> , 2002, 111, 393-405.	28.9	283
99	Interaction of the Fanconi Anemia Proteins and BRCA1 in a Common Pathway. <i>Molecular Cell</i> , 2001, 7, 249-262.	9.7	1,125
100	BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function. <i>Cell</i> , 2001, 105, 149-160.	28.9	606
101	Tumorigenesis in mice carrying a truncating Brca1 mutation. <i>Genes and Development</i> , 2001, 15, 1188-1193.	5.9	118
102	Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. <i>Nature Genetics</i> , 2000, 26, 85-88.	21.4	297
103	Genetic Analysis of BRCA1 Function in a Defined Tumor Cell Line. <i>Molecular Cell</i> , 1999, 4, 1093-1099.	9.7	332
104	A hybrid approach to modeling the dynamics of macromolecules. <i>Journal of Chemical Physics</i> , 1986, 85, 3655-3673.	3.0	14
105	Genomic landscape of lymphatic malformations: a case series and response to the PI3K inhibitor alpelisib in an N-of-1 clinical trial. <i>ELife</i> , 0, 11, .	6.0	8